Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Gefässchirurgie
Erschienen in: Gefässchirurgie 5/2022

25.08.2022 | Arteriosklerose | Leitthema

Molekulare Biomarker der Atherosklerose

verfasst von: Amun G. Hofmann, Christoph J. Binder

Erschienen in: Gefässchirurgie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Hoffnung, durch im Blut zirkulierende Biomarker Rückschlüsse auf lokale atherosklerotische Prozesse zu generieren, hat in der Vergangenheit zur Erforschung einer Vielzahl von unterschiedlichen Molekülen geführt. Dennoch stehen signifikante Durchbrüche bis dato aus. Dies ist mitunter durch die komplexe Pathogenese atherosklerotischer Erkrankungen bedingt, aber auch durch methodologische Hindernisse in der Exploration selbst. In der vorliegenden Übersichtsarbeit werden diverse Biomarker im Zusammenhang mit der zugrunde liegenden Phase der Atherogenese vorgestellt. Ein Schwerpunkt liegt insbesondere auch auf der Aufschlüsselung von rein krankheitsassoziierten Markern und pathophysiologisch funktionellen Mediatoren.
Literatur
1.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A et al (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1459–1544CrossRef
2.
Gijsberts CM, Agostoni P, Hoefer IE, Asselbergs FW, Pasterkamp G, Nathoe H et al (2015) Gender differences in health-related quality of life in patients undergoing coronary angiography. Open Heart 2(1):e231CrossRefPubMedPubMedCentral
3.
Haitjema S, de Borst G‑J, de Vries J‑P, Moll F, Pasterkamp G, den Ruijter H (2014) Health-related quality of life is poor but does not vary with cardiovascular disease burden among patients operated for severe atherosclerotic disease. IJC Heart Vessel 4:53–58CrossRef
4.
Lecca M, Saba L, Sanfilippo R, Pintus E, Cadoni M, Sancassiani F et al (2016) Quality of life in carotid atherosclerosis: the role of co-morbid mood disorders. Clin Pract Epidemiol Ment Health 12:1–8CrossRefPubMedPubMedCentral
5.
Rawashdeh SI, Ibdah R, Kheirallah KA, Al-Kasasbeh A, Raffee LA, Alrabadi N et al (2021) Prevalence estimates, severity, and risk factors of depressive symptoms among coronary artery disease patients after ten days of percutaneous coronary intervention. Clin Pract Epidemiol Ment Health 17:103–113CrossRefPubMedPubMedCentral
6.
Ohsfeldt RL, Gandhi SK, Fox KM, Bullano MF, Davidson M (2010) Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ 13(3):500–507CrossRefPubMed
7.
Costa J, Alarcão J, Amaral-Silva A, Araújo F, Ascenção R, Caldeira D et al (2021) Atherosclerosis: the cost of illness in Portugal. Rev Port Cardiol (Engl Ed) 40(6):409–419CrossRef
8.
Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD et al (2013) Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet 381(9873):1211–1222CrossRefPubMed
9.
Gisterå A, Hansson GK (2017) The immunology of atherosclerosis. Nat Rev Nephrol 13(6):368–380CrossRefPubMed
10.
Ley K, Miller YI, Hedrick CC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31(7):1506–1516CrossRefPubMedPubMedCentral
11.
van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD et al (2016) Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134(8):611–624CrossRefPubMedPubMedCentral
12.
13.
Sage AP, Tsiantoulas D, Binder CJ, Mallat Z (2019) The role of B cells in atherosclerosis. Nat Rev Cardiol 16(3):180–196CrossRefPubMed
14.
Winkels H, Ehinger E, Vassallo M, Buscher K, Dinh HQ, Kobiyama K et al (2018) Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res 122(12):1675–1688CrossRefPubMedPubMedCentral
15.
Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S (2016) Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 118(4):535–546CrossRefPubMed
16.
Schiffrin EL, Lipman ML, Mann JFE (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116(1):85–97CrossRefPubMed
17.
Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P et al (2015) Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults. J Am Coll Cardiol 65(11):1065–1074CrossRefPubMed
18.
van Staa T‑P, Gulliford M, Ng ES‑W, Goldacre B, Smeeth L (2014) Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: How well do they predict individual rather than population risk? Plos One 9(10):e106455CrossRefPubMedPubMedCentral
19.
Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L et al (2020) Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation 142(7):621–642CrossRefPubMedPubMedCentral
20.
Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz JM, Mendiguren J et al (2017) Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol 70(24):2979–2991CrossRefPubMed
21.
Koenig W, Khuseyinova N (2007) Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27(1):15–26CrossRefPubMed
22.
Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K et al (2002) Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22(10):1649–1654CrossRefPubMed
23.
Huang Y, Mironova M, Lopes-Virella MF (1999) Oxidized LDL stimulates matrix metalloproteinase‑1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 19(11):2640–2647CrossRefPubMed
24.
Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB et al (1999) Oxidized low-density lipoprotein regulates matrix metalloproteinase‑9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99(8):993–998CrossRefPubMed
25.
Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL (2003) LOX‑1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 107(4):612–617CrossRefPubMed
26.
Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112(5):651–657CrossRefPubMed
27.
Wang A, Yang Y, Su Z, Yue W, Hao H, Ren L et al (2017) Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes. Stroke 48(1):91–97CrossRefPubMed
28.
29.
Koenig W, Karakas M, Zierer A, Herder C, Baumert J, Meisinger C et al (2011) Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg study. Clin Chem 57(8):1196–1200CrossRefPubMed
30.
Itabe H, Ueda M (2007) Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14(1):1–11CrossRefPubMed
31.
32.
Miller NE, Thelle DS, Forde OH, Mjos OD (1977) The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1(8019):965–968CrossRefPubMed
33.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62(5):707–714CrossRefPubMed
34.
Johnsen SH, Mathiesen EB, Fosse E, Joakimsen O, Stensland-Bugge E, Njølstad I et al (2005) Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis: the Tromsø study. Circulation 112(4):498–504CrossRefPubMed
35.
Touboul P‑J, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A et al (2014) HDL‑C, triglycerides and carotid IMT: a meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis 232(1):65–71CrossRefPubMed
36.
Yin J, Yu C, Liu H, Du M, Sun F, Yu C et al (2020) A model to predict unstable carotid plaques in population with high risk of stroke. BMC Cardiovasc Disord 20(1):164CrossRefPubMedPubMedCentral
37.
Nichols GA, Vupputuri S, Rosales AG (2011) Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 108(8):1124–1128CrossRefPubMed
38.
Omote K, Yokota I, Nagai T, Sakuma I, Nakagawa Y, Kamiya K et al (2022) High-density lipoprotein cholesterol and cardiovascular events in patients with stable coronary artery disease treated with statins: an observation from the REAL-CAD study. J Atheroscler Thromb 29(1):50–68CrossRefPubMed
39.
Tiozzo E, Gardener H, Hudson BI, Dong C, Della-Morte D, Crisby M et al (2014) High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan study. Atherosclerosis 237(1):163–168CrossRefPubMedPubMedCentral
40.
Tall AR, Rader DJ (2018) Trials and tribulations of CETP inhibitors. Circ Res 122(1):106–112CrossRefPubMed
41.
Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study. Circulation 117(2):176–184CrossRefPubMed
42.
Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4):412–423CrossRef
43.
Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U et al (2015) Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 242(2):496–503CrossRefPubMed
44.
Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2013) Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 61(11):1146–1156CrossRefPubMed
45.
Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M et al (2014) Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol 64(9):851–860CrossRefPubMed
46.
Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK (2019) Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J 71(2):99–112CrossRefPubMedPubMedCentral
47.
Ugovšek S, Šebeštjen M (2021) Lipoprotein(a)—the crossroads of atherosclerosis, atherothrombosis and inflammation. Biomolecules 12(1):26CrossRefPubMedPubMedCentral
48.
Kronenberg F, Tsimikas S (2019) The challenges of measuring Lp(a): a fight against Hydra? Atherosclerosis 289:181–183CrossRefPubMed
49.
50.
Zalewski A, MacPhee C (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25(5):923–931CrossRefPubMed
51.
Lind L, Simon T, Johansson L, Kotti S, Hansen T, Machecourt J et al (2012) Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J 33(23):2946–2954CrossRefPubMed
52.
Sarlon-Bartoli G, Boudes A, Buffat C, Bartoli MA, Piercecchi-Marti MD, Sarlon E et al (2012) Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. Eur J Vasc Endovasc Surg 43(2):154–159CrossRefPubMed
53.
Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A‑I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358(9298):2026–2033CrossRefPubMed
54.
Benn M, Nordestgaard BG, Jensen GB, Tybjærg-Hansen A (2007) Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen city heart study. Arterioscler Thromb Vasc Biol 27(3):661–670CrossRefPubMed
55.
Benn M (2009) Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis 206(1):17–30CrossRefPubMed
56.
Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F et al (2016) Association between anti-apolipoprotein A‑1 antibodies and cardiovascular disease in the general population: results from the CoLaus study. Thromb Haemost 116(10):764–771CrossRefPubMed
57.
Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952CrossRefPubMed
58.
Dong H, Chen W, Wang X, Pi F, Wu Y, Pang S et al (2015) Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case–control study. Metab Brain Dis 30(6):1319–1330CrossRefPubMed
59.
Paternoster L, Martínez González NA, Lewis S, Sudlow C (2008) Association between apolipoprotein E genotype and carotid intima-media thickness may suggest a specific effect on large artery atherothrombotic stroke. Stroke 39(1):48–54CrossRefPubMed
60.
Khan TA, Shah T, Prieto D, Zhang W, Price J, Fowkes GR et al (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 42(2):475–492CrossRefPubMedPubMedCentral
61.
Sofat R, Cooper JA, Kumari M, Casas JP, Mitchell JP, Acharya J et al (2016) Circulating apolipoprotein E concentration and cardiovascular disease risk: meta-analysis of results from three studies. PLoS Med 13(10):e1002146CrossRefPubMedPubMedCentral
62.
Seidah NG, Awan Z, Chrétien M, Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114(6):1022–1036CrossRefPubMed
63.
Chan DC, Pang J, McQuillan BM, Hung J, Beilby JP, Barrett PHR et al (2016) Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults. Heart Lung Circ 25(5):520–525CrossRefPubMed
64.
Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N et al (2016) Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: a systematic review and meta-analysis. Atherosclerosis 252:50–60CrossRefPubMed
65.
66.
Kampoli A‑M, Tousoulis D, Antoniades C, Siasos G, Stefanadis C (2009) Biomarkers of premature atherosclerosis. Trends Mol Med 15(7):323–332CrossRefPubMed
67.
Martinez E, Martorell J, Riambau V (2020) Review of serum biomarkers in carotid atherosclerosis. J Vasc Surg 71(1):329–341CrossRefPubMed
68.
69.
Kigka VI, Potsika V, Mantzaris M, Tsakanikas V, Koncar I, Fotiadis DI (2021) Serum biomarkers in carotid artery disease. Diagnostics 11(11):2143CrossRefPubMedPubMedCentral
70.
Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL et al (2005) C‑reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112(1):25–31CrossRefPubMed
71.
Debing E, Peeters E, Demanet C, De Waele M, Van den Brande P (2008) Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study. Vasc Endovascular Surg 42(2):122–127CrossRefPubMed
72.
Schulze Horn C, Ilg R, Sander K, Bickel H, Briesenick C, Hemmer B et al (2009) High-sensitivity C‑reactive protein at different stages of atherosclerosis: results of the INVADE study. J Neurol 256(5):783–791CrossRefPubMed
73.
Puz P, Lasek-Bal A, Ziaja D, Kazibutowska Z, Ziaja K (2013) Inflammatory markers in patients with internal carotid artery stenosis. Arch Med Sci 9(2):254–260CrossRefPubMedPubMedCentral
74.
Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C‑reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 75(9709):132–140
75.
van Wijk DF, Boekholdt SM, Wareham NJ, Ahmadi-Abhari S, Kastelein JJP, Stroes ESG et al (2013) C‑reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-norfolk cohort study. Arterioscler Thromb Vasc Biol 33(12):2888–2894CrossRefPubMed
76.
Zhuang Q, Shen C, Chen Y, Zhao X, Wei P, Sun J et al (2019) Association of high sensitive C‑reactive protein with coronary heart disease: a Mendelian randomization study. BMC Med Genet 20(1):170CrossRefPubMedPubMedCentral
77.
McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C et al (2003) Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 92(2):194–199CrossRefPubMed
78.
Santos S, Rooke TW, Bailey KR, McConnell JP, Kullo IJ (2004) Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle brachial index. Vasc Med 9(3):171–176CrossRefPubMed
79.
Chapman CML, Beilby JP, McQuillan BM, Thompson PL, Hung J (2004) Monocyte count, but not C‑reactive protein or interleukin‑6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35(7):1619–1624CrossRefPubMed
80.
Nylænde M, Kroese A, Stranden E, Morken B, Sandbæk G, Lindahl A et al (2006) Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 11(1):21–28CrossRefPubMed
81.
Lorenz MW, Karbstein P, Markus HS, Sitzer M (2007) High-sensitivity C‑reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. Stroke 38(6):1774–1779CrossRefPubMed
82.
Halvorsen DS, Johnsen SH, Mathiesen EB, Njølstad I (2009) The association between inflammatory markers and carotid atherosclerosis is sex dependent: the Tromsø study. Cerebrovasc Dis 27(4):392–397CrossRefPubMed
83.
Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M et al (2010) Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C‑reactive protein in stable coronary artery disease. PLoS Med 7(6):e1000286CrossRefPubMedPubMedCentral
84.
Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y et al (2017) Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis 259:75–82CrossRefPubMed
85.
Singh TP, Morris DR, Smith S, Moxon JV, Golledge J (2017) Systematic review and meta-analysis of the association between C‑reactive protein and major cardiovascular events in patients with peripheral artery disease. Eur J Vasc Endovasc Surg 54(2):220–233CrossRefPubMed
86.
Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al (2009) Genetic loci associated with C‑reactive protein levels and risk of coronary heart disease. JAMA 302(1):37–48CrossRefPubMedPubMedCentral
87.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107(3):499–511CrossRefPubMed
88.
Voudris KV, Chanin J, Feldman DN, Charitakis K (2015) Novel inflammatory biomarkers in coronary artery disease: potential therapeutic approaches. Curr Med Chem 22(22):2680–2689CrossRefPubMed
89.
Soeki T, Sata M (2016) Inflammatory biomarkers and atherosclerosis. Int Heart J 57(2):134–139CrossRefPubMed
90.
Lv J‑X, Kong Q, Ma X (2017) Current advances in circulating inflammatory biomarkers in atherosclerosis and related cardio-cerebrovascular diseases. Chronic Dis Transl Med 3(4):207–212PubMedPubMedCentral
91.
Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GDO, Collins R et al (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294(14):1799–1809
92.
Zhang B, Li X‑L, Zhao C‑R, Pan C‑L, Zhang Z (2018) Interleukin‑6 as a predictor of the risk of cardiovascular disease: a meta-analysis of prospective epidemiological studies. Immunol Invest 47(7):689–699CrossRefPubMed
93.
Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M et al (2021) IL‑6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10289):2060–2069CrossRefPubMed
94.
Weinhold B, Bader A, Poli V, Rüther U (1997) Interleukin‑6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo. Biochem J 325(3):617–621CrossRefPubMedPubMedCentral
95.
Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100(8):793–798CrossRefPubMed
96.
Ørn S, Ueland T, Manhenke C, Sandanger Ø, Godang K, Yndestad A et al (2012) Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med 272(3):267–276CrossRefPubMed
97.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131CrossRefPubMed
98.
Libby P (2017) Interleukin‑1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 70(18):2278–2289CrossRefPubMedPubMedCentral
99.
Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251–262CrossRefPubMed
100.
Olejarz W, Łacheta D, Kubiak-Tomaszewska G (2020) Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. Int J Mol Sci 21(11):E3946CrossRefPubMed
101.
Alvarez B, Ruiz C, Chacón P, Alvarez-Sabin J, Matas M (2004) Serum values of metalloproteinase‑2 and metalloproteinase‑9 as related to unstable plaque and inflammatory cells in patients with greater than 70 % carotid artery stenosis. J Vasc Surg 40(3):469–475CrossRefPubMed
102.
Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al (1998) Peripheral blood levels of matrix metalloproteases‑2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32(2):368–372CrossRefPubMed
103.
Wang L‑X, Lü S‑Z, Zhang W‑J, Song X‑T, Chen H, Zhang L‑J (2011) Comparision of high sensitivity C‑reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques. Chin Med J 124(11):1657–1661PubMed
104.
Romero JR, Vasan RS, Beiser AS, Polak JF, Benjamin EJ, Wolf PA et al (2008) Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring study. J Stroke Cerebrovasc Dis 17(6):412–417CrossRefPubMedPubMedCentral
105.
Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107(12):1579–1585CrossRefPubMed
106.
Pelisek J, Rudelius M, Zepper P, Poppert H, Reeps C, Schuster T et al (2009) Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc Dis 28(6):601–610CrossRefPubMed
107.
Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PRF, Naylor AR et al (2004) Unstable carotid plaques exhibit raised matrix metalloproteinase‑8 activity. Circulation 110(3):337–343CrossRefPubMed
108.
Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase‑9 and tissue inhibitor of metalloproteinase‑1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141(2):211–217CrossRefPubMed
109.
Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Cresti S et al (2005) Metalloproteinases and their inhibitors are markers of plaque instability. Surgery 137(3):355–363CrossRefPubMed
110.
Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT et al (2006) Tissue inhibitor of metalloproteinase‑1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151(5):1101.e1–1101.e8CrossRef
111.
Glogowska-Ligus J, Szadorska B, Dabek J (2013) Transcription activity of MMP‑2 and MMP‑9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. J Postgrad Med 59(2):115CrossRefPubMed
112.
Sangiorgi G, Mauriello A, Bonanno E, Oxvig C, Conover CA, Christiansen M et al (2006) Pregnancy-associated plasma protein‑A is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques. J Am Coll Cardiol 47(11):2201–2211CrossRefPubMed
113.
Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR et al (2001) Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345(14):1022–1029CrossRefPubMed
114.
Lund J, Qin Q‑P, Ilva T, Pettersson K, Voipio-Pulkki L‑M, Porela P et al (2003) Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 108(16):1924–1926CrossRefPubMed
115.
Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM et al (2005) Pregnancy-associated plasma protein‑A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 45(2):229–237CrossRefPubMed
116.
Alsulaimani S, Gardener H, Elkind MSV, Cheung K, Sacco RL, Rundek T (2013) Elevated homocysteine and carotid plaque area and densitometry in the Northern Manhattan study. Stroke 44(2):457–461CrossRefPubMedPubMedCentral
117.
Jia J, Wang A, Wang J, Wu J, Yan X, Zhou Y et al (2016) Homocysteine and its relationship to asymptomatic carotid stenosis in a Chinese community population. Sci Rep 6(1):37361CrossRefPubMedPubMedCentral
118.
Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D (1998) Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 18(12):1895–1901CrossRefPubMed
119.
Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM (1998) Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 158(8):862–867CrossRefPubMed
120.
Homocysteine Studies Collaboration (2002) Homocysteine and risk of Ischemic heart disease and stroke: a meta-analysis. JAMA 288(16):2015CrossRef
121.
Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M et al (2012) Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 9(2):e1001177CrossRefPubMedPubMedCentral
122.
van Meurs JBJ, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH et al (2013) Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr 98(3):668–676CrossRefPubMedPubMedCentral
123.
Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF (2008) Homocysteine or renal impairment: Which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 28(6):1158–1164CrossRefPubMed
124.
O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402CrossRef
125.
Gao W, He H‑W, Wang Z‑M, Zhao H, Lian X‑Q, Wang Y‑S et al (2012) Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 11:55CrossRefPubMedPubMedCentral
126.
Gacoń J, Kabłak-Ziembicka A, Stępień E, Enguita FJ, Karch I, Derlaga B et al (2016) Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol 74(3):280–288CrossRefPubMed
127.
Gao H, Guddeti RR, Matsuzawa Y, Liu L‑P, Su L‑X, Guo D et al (2015) Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PLoS ONE 10(5):e123477CrossRefPubMedPubMedCentral
128.
Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C et al (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107(5):677–684CrossRefPubMed
129.
Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P (2016) Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res 111(4):322–337CrossRefPubMedPubMedCentral
130.
131.
Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A et al (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358(20):2107–2116CrossRefPubMed
132.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRefPubMed
133.
Andras A, Stansby G, Hansrani M (2013) Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev 7:CD3285
134.
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M (2017) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 8:CD6612PubMed
135.
136.
Ambale-Venkatesh B, Yang X, Wu CO, Liu K, Hundley WG, McClelland R et al (2017) Cardiovascular event prediction by machine learning: the multi-ethnic study of atherosclerosis. Circ Res 121(9):1092–1101CrossRefPubMedPubMedCentral
137.
138.
Ben Braiek A, Chahed H, Dumont F, Abdelhak F, Hichem D, Gamra H et al (2021) Identification of biomarker panels as predictors of severity in coronary artery disease. J Cell Mol Med 25(3):1518–1530CrossRefPubMed
139.
Ge J, Song C, Zhang C, Liu X, Chen J, Dou K et al (2020) Personalized early-warning signals during progression of human coronary atherosclerosis by landscape dynamic network biomarker. Genes 11(6):676CrossRefPubMedCentral
140.
Núñez E, Fuster V, Gómez-Serrano M, Valdivielso JM, Fernández-Alvira JM, Martínez-López D et al (2022) Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis. EBioMedicine 76:103874CrossRefPubMedPubMedCentral
141.
Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H et al (2014) BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. Eur J Epidemiol 29(10):777–790CrossRefPubMedPubMedCentral
142.
Metadaten
Titel
Molekulare Biomarker der Atherosklerose
verfasst von
Amun G. Hofmann
Christoph J. Binder
Publikationsdatum
25.08.2022
Verlag
Springer Medizin
Erschienen in
Gefässchirurgie / Ausgabe 5/2022
Print ISSN: 0948-7034
Elektronische ISSN: 1434-3932
DOI
https://doi.org/10.1007/s00772-022-00914-0

Weitere Artikel der Ausgabe 5/2022

Gefässchirurgie 5/2022 Zur Ausgabe

Leitthema

Evolution der Translation: Von der populationsbasierten zur individualisierten Gefäßmedizin

Leitthema

Überwachung von motorisch evozierten Potenzialen

Wunde

Erste Erfahrungen mit der Bio-Zellulose Nanogen Aktiv in der Behandlung komplexer Wunden

Netzwerk Grundlagenforschung

Die Rolle der Matrix-Metalloproteinasen 2 und 9 in der Pathogenese des Aortenaneurysmas

Leitthema

Vom Crashtest in den OP: Optimierung des Stentgraft-Designs mittels Numerischer Simulation

Mitteilungen der DGG

Mitteilungen der DGG

Passend zum Thema

ANZEIGE

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Vorhofflimmern

Die neue Leitlinie zur Behandlung von Herzklappenerkrankungen der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS) ist ab jetzt als deutschsprachige Pocket-Leitlinien abrufbar. Die wichtigsten Neuerungen des Updates finden Sie hier von Prof. Dr. Helge Möllmann aus Dortmund für Sie zusammengefasst.

ANZEIGE

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Vorhofflimmern

Der interventionelle Verschluss des linken Vorhofohrs ist eine in den Leitlinien empfohlene Alternative zur oralen Antikoagulation bei Menschen mit Vorhofflimmern. Bei welchen Patientinnen und Patienten Sie konkret an diese Alternative denken sollten – dazu gibt Kardiologe PD Dr. Zisis Dimitriadis alltagstaugliche Tipps.

ANZEIGE

Abbott Structural Heart

Content Hub

Wir helfen Menschen mit Strukturellen Herzerkrankungen ihre Lebensqualität zu verbessern. Entdecken Sie unser einzigartiges Produktportfolio für ihre Patienten.

Abbott Medical GmbH
Bildnachweise